睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07099274,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. At least one measurable target lesion confirmed by screening imaging per RECIST v1.1;

    入选标准第 8 条

    Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma;

    入选标准第 12 条

  3. Child-Pugh class A or class B (score ≤7) without hepatic encephalopathy history;

    入选标准第 6 条

  4. ECOG performance status 0-2;

    入选标准第 5 条

  5. Active HBV/HCV infection requires ongoing antiviral therapy; k.Fertile patients must use highly effective contraception with partners during treatment and ≥180 days post-last dose.

    入选标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07099274,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Comprehension and voluntary signing of the study's informed consent form;
  2. Age ≥18 years, any gender;
  3. Histologically or clinically confirmed hepatocellular carcinoma;
  4. Documented failure or intolerance to first-line therapy with PD-1/PD-L1 inhibitor plus bevacizumab;
  5. ECOG performance status 0-2;
  6. Child-Pugh class A or class B (score ≤7) without hepatic encephalopathy history;
  7. Life expectancy ≥3 months;
  8. At least one measurable target lesion confirmed by screening imaging per RECIST v1.1;
  9. Adequate organ and bone marrow function within 7 days prior to initial study treatment;
  10. Active HBV/HCV infection requires ongoing antiviral therapy; k.Fertile patients must use highly effective contraception with partners during treatment and ≥180 days post-last dose.
  11. Inability to comply with the study protocol or procedures;
  12. Histologically/cytologically confirmed fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma;
  13. History of liver transplantation or planned transplantation;
  14. Presence of central nervous system metastases and/or leptomeningeal carcinomatosis;
  15. Baseline imaging showing Vp4 portal vein tumor thrombosis;
  16. Hypersensitivity to any study drug components or history of severe allergic reactions;
  17. Concurrent HBV and HCV co-infection;
  18. Clinically significant ascites requiring intervention during screening;
  19. Concurrent use of other investigational drugs or participation in another clinical trial within 4 weeks prior to enrollment;
  20. Esophageal/gastric variceal bleeding due to portal hypertension within 6 months before treatment initiation, or high-risk varices on endoscopy within 3 months;
  21. Current interstitial lung disease (ILD), history of steroid-required ILD, or other pulmonary fibrosis/organizing pneumonia affecting immune-related pulmonary toxicity assessment;
  22. Uncontrolled hypertension (SBP≥160 mmHg and/or DBP≥100 mmHg despite medication), coronary artery disease, arrhythmias, or heart failure (NYHA Class ≥II);
  23. Uncontrolled clinically significant infections requiring IV antimicrobial therapy;
  24. Proteinuria ≥2+ (≥1.0g/24h);
  25. History of hemorrhagic tendency regardless of severity within 2 months prior to enrollment;
  26. Arterial/venous thromboembolic events within 12 months before treatment initiation (e.g., cerebrovascular accident including TIA);
  27. Acute myocardial infarction, acute coronary syndrome, or CABG within 6 months before treatment;
  28. Unhealed fractures or chronic non-healing wounds;
  29. Coagulopathy, bleeding diathesis, or current therapeutic anticoagulation;
  30. Other malignancies within 5 years except curatively resected basal/squamous cell skin carcinoma or cervical carcinoma in situ;
  31. Active autoimmune disease or autoimmune disease history requiring immunosuppression within 4 weeks prior to enrollment;
  32. Prior allogeneic bone marrow or solid organ transplantation;
  33. Investigator assessment of ineligibility based on medical/safety reasons.

排除标准:Exclusion Criteria:

    引自 ClinicalTrials.gov, NCT07099274, 参与标准,读取于 2026年11月10日。

    这些信息从哪里来

    登记记录

    ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07099274,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

    疾病与医院

    本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

    没有收录的内容

    登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

    提出更正ClinicalTrials.gov NCT07099274